HUTCHMED: Flow of catalysts continues, with more into 2025
HUTCHMED continues to focus on clinical and commercial delivery from its most advanced in-house pipeline assets. The goal is sustainable profitability from FY25 onwards, with an expectation for FY24 Oncology/Immunology consolidated revenues of $300-$400m, driven by targeted 30-50% growth in marketed product sales and royalties. First Japan approval of fruquintinib for advanced metastatic colorectal cancer (mCRC) is a key achievement, although the remainder of 2024 into early-2025 should bring further regulatory catalysts. These include a potential China approval decision for first immunology/haem-oncology asset, sovleplenib, in ≥2L ITP (immune thrombocytopenia), and the potential first global savolitinib filing with the FDA in lung cancer. Our updated HUTCHMED valuation is $5.94bn/£4.95bn/HK$46.31bn , equivalent to $34.07/ADS and 568p/HK$53.14 per share.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.